Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Evolus, Inc. (EOLS)
USD5.91
-0.36 (-5.70%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
520 Newport Center Drive 92660
Newport Beach, CA, US
Newport Beach, CA, US
CEO
David Moatazedi
Website
evolus.com
IPO
2018-02-08
CIK 1570562 ISIN US30052C1071
Also trades on
London Stock Exchange · 0K16.L (USD)
NASDAQ Global Market · EOLS (USD)
Description
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.91
-0.36 (-5.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
821.5K
Beta
1.32
Float Shares
49.24M
Free Float %
75.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.63% | +0.32% | +48.01% | +47.66% | -13.42% | -4.96% | -36.67% | -38.40% | -24.94% | -45.04% | -45.04% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
5.91
Low
13.00
+119.9%
Consensus
15.00
+153.7%
Median
15.00
+153.7%
High
17.00
+187.5%
DCF (Unlevered)
8.49
+43.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 4 |
16.00
+170.6%
|
| All Time | 8 |
19.00
+221.3%
|
Quality scores
Altman Z-Score
-1.85
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+11.6% ★ Q1'26: +6.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+1.2% Q1'26: +46.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-25.3% Q1'26: -14.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-12.7% Q1'26: -8.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-48.2% Q1'26: -29.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.0% Q1'26: +2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-5.37× Q1'26: -10.98× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 7 Rev. Ana. 5 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
34.93M
est: 33.46M (+4.4%)
|
56.54M
est: 57.10M (-1.0%)
|
99.67M
est: 99.77M (-0.1%)
|
148.62M
est: 148.81M (-0.1%)
|
202.09M
est: 237.26M (-14.8%)
|
266.27M
est: 266.30M (0.0%)
|
297.18M
est: 296.47M (+0.2%)
|
330.50M
329.39M – 331.61M
+11.5% YoY
|
387.72M
383.58M – 390.37M
+17.3% YoY
|
459.05M
459.04M – 459.05M
+18.4% YoY
|
528.17M
520.06M – 534.66M
+15.1% YoY
|
591.96M
582.86M – 599.22M
+12.1% YoY
|
| EBITDA |
-92.10M
est: -99.12M (+7.1%)
|
-144.75M
est: -23.47M (-516.8%)
|
-39.06M
est: -41.00M (+4.7%)
|
-53.85M
est: -76.24M (+29.4%)
|
-41.81M
est: 53.41M (-178.3%)
|
-25.00M
est: 59.95M (-141.7%)
|
-28.86M
est: 66.74M (-143.2%)
|
74.40M
74.15M – 74.65M
+11.5% YoY
|
87.28M
86.35M – 87.88M
+17.3% YoY
|
103.34M
103.33M – 103.34M
+18.4% YoY
|
118.90M
117.07M – 120.36M
+15.1% YoY
|
133.25M
131.21M – 134.89M
+12.1% YoY
|
| EBIT |
-97.11M
est: -114.72M (+15.3%)
|
-152.43M
est: -25.07M (-508.1%)
|
-45.37M
est: -43.80M (-3.6%)
|
-57.58M
est: -83.20M (+30.8%)
|
-47.68M
est: 51.65M (-192.3%)
|
-31.02M
est: 57.97M (-153.5%)
|
-37.60M
est: 64.54M (-158.3%)
|
71.94M
71.70M – 72.19M
+11.5% YoY
|
84.40M
83.50M – 84.98M
+17.3% YoY
|
99.93M
99.93M – 99.93M
+18.4% YoY
|
114.97M
113.21M – 116.39M
+15.1% YoY
|
128.86M
126.88M – 130.44M
+12.1% YoY
|
| Net Income |
-90.03M
est: -97.34M (+7.5%)
|
-163.01M
est: -107.99M (-51.0%)
|
-46.81M
est: -60.42M (+22.5%)
|
-74.41M
est: -66.37M (-12.1%)
|
-61.69M
est: -58.08M (-6.2%)
|
-50.42M
est: -17.37M (-190.2%)
|
-51.64M
est: -29.72M (-73.8%)
|
-7.41M
-11.45M – -3.37M
+75.1% YoY
|
18.02M
13.86M – 22.18M
+343.3% YoY
|
23.57M
21.78M – 58.53M
+30.7% YoY
|
73.49M
72.03M – 74.67M
+211.9% YoY
|
96.96M
95.03M – 98.51M
+31.9% YoY
|
| SGA |
113.59M
est: 35.97M (+215.8%)
|
98.19M
est: 61.39M (+60.0%)
|
112.07M
est: 107.26M (+4.5%)
|
141.84M
est: 159.98M (-11.3%)
|
164.94M
est: 207.92M (-20.7%)
|
198.03M
est: 233.36M (-15.1%)
|
220.79M
est: 259.80M (-15.0%)
|
289.62M
288.65M – 290.60M
+11.5% YoY
|
339.77M
336.14M – 342.09M
+17.3% YoY
|
402.27M
402.27M – 402.27M
+18.4% YoY
|
462.85M
455.74M – 468.53M
+15.1% YoY
|
518.74M
510.77M – 525.11M
+12.1% YoY
|
| EPS |
-3.19
est: -3.09 (-3.3%)
|
-4.83
est: -1.74 (-177.4%)
|
-0.94
est: -0.97 (+3.5%)
|
-1.33
est: -0.92 (-44.6%)
|
-1.08
est: -0.90 (-19.6%)
|
-0.81
est: -0.27 (-200.0%)
|
-0.80
est: -0.45 (-77.5%)
|
-0.09
-0.18 – -0.05
+79.1% YoY
|
0.27
0.22 – 0.34
+383.7% YoY
|
0.67
0.34 – 0.91
+150.2% YoY
|
1.14
1.12 – 1.16
+70.9% YoY
|
1.50
1.47 – 1.53
+31.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-40.47M
OE per share TTM
-0.62
Owner's Yield
-9.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
26
Total invested
8.38M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alphaeon 1 LLC | 8.66M | 25.90% | 8.66M | — | 8.66M | 10.00 | OO | Delaware | 2020-01-17 | ↗ |
| 2 | Inc. | 6.76M | 16.70% | 6.76M | — | 6.76M | — | CO | NUMBER OF | 2021-03-01 | ↗ |
| 3 | (1) BlackRock, Inc. | 3.34M | 5.80% | 3.27M | — | 3.34M | — | HC | Delaware | 2024-01-29 | ↗ |
| 4 | First Manhattan Co. | 3.33M | 6.00% | 3.33M | — | 3.33M | — | BD, IA | New York | 2022-02-15 | ↗ |
| 5 | Israel A. Englander | 3.33M | 5.90% | — | 3.33M | — | 3.33M | IN | — | 2023-02-15 | ↗ |
| 6 | Millennium Group Management LLC | 3.33M | 5.90% | — | 3.33M | — | 3.33M | OO | — | 2023-02-15 | ↗ |
| 7 | Millennium Management LLC | 3.33M | 5.90% | — | 3.33M | — | 3.33M | OO | — | 2023-02-15 | ↗ |
| 8 | Daewoong Pharmaceutical Co., Ltd. | 3.14M | 7.20% | 3.14M | — | 3.14M | — | CO | Republic of Korea | 2021-04-01 | ↗ |
| 9 | Advisors LLC | 3.09M | 5.40% | — | 3.09M | — | 3.09M | IA | Delaware | 2023-11-27 | ↗ |
| 10 | Edelman | 3.09M | 5.40% | — | 3.09M | — | 3.09M | IN | Delaware | 2023-11-27 | ↗ |
| 11 | Sciences Master Fund, Ltd. | 3.09M | 5.40% | — | 3.09M | — | 3.09M | CO | Delaware | 2023-11-27 | ↗ |
| 12 | Tang Capital Management, LLC | 3.04M | 5.40% | — | 3.04M | — | 3.04M | OO | DELAWARE | 2023-02-21 | ↗ |
| 13 | Company, L.P. | 3.03M | 5.41% | — | 3.03M | — | — | PN | Delaware | 2022-06-06 | ↗ |
| 14 | Deerfield Mgmt, L.P. | 3.03M | 5.41% | — | 3.03M | — | — | PN | Delaware | 2022-06-06 | ↗ |
| 15 | Deerfield Partners, L.P. | 3.03M | 5.41% | — | 3.03M | — | — | PN | Delaware | 2022-06-06 | ↗ |
| 16 | James E. Flynn | 3.03M | 5.41% | — | 3.03M | — | — | IN | United States | 2022-06-06 | ↗ |
| 17 | The Vanguard Group - 23-1945930 | 2.94M | 5.15% | — | — | — | — | IA | Pennsylvania | 2024-02-13 | ↗ |
| 18 | Daniel Mack | 2.91M | 5.10% | — | 2.91M | — | — | HC | MA | 2024-02-14 | ↗ |
| 19 | Nantahala Capital Management, LLC | 2.91M | 5.10% | — | 2.91M | — | — | IA | MA | 2024-02-14 | ↗ |
| 20 | Wilmot B. Harkey | 2.91M | 5.10% | — | 2.91M | — | — | HC | MA | 2024-02-14 | ↗ |
| 21 | Wellington Group Holdings LLP | 1.52M | 5.58% | — | 1.42M | — | — | HC | Massachusetts | 2019-02-12 | ↗ |
| 22 | Wellington Investment Advisors Holdings LLP | 1.52M | 5.58% | — | 1.42M | — | — | HC | Massachusetts | 2019-02-12 | ↗ |
| 23 | Wellington Management Group LLP | 1.52M | 5.58% | — | 1.42M | — | — | HC | Massachusetts | 2019-02-12 | ↗ |
| 24 | Wellington Management Company LLP | 1.44M | 5.28% | — | 1.40M | — | — | IA | Massachusetts | 2019-02-12 | ↗ |
| 25 | TIMOTHY J. MCDONALD | 425.5K | 7.04% | — | 1.93M | — | 1.93M | IN | DELAWARE | 2019-11-18 | ↗ |
| 26 | Stonepine Capital Management, LLC | 9.00 | 7.40% | — | 4.19M | — | 4.19M | IA, OO | California | 2023-06-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
26
-146 vs prev Q
New positions
5
Closed positions
147
Increased
14
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 744.2K +744.2K (+100.0%) | 4.95B +4.9B (+100.0%) | 1.15% +1.150 pp | 3.48% +3.483 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 2 | POTOMAC CAPITAL MANAGEMENT, INC. | 141.2K +141.2K (+100.0%) | 938.79M +938.8M (+100.0%) | 0.22% +0.218 pp | 0.75% +0.754 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 3 | NANTAHALA CAPITAL MANAGEMENT, LLC | 5.82M +93.8K (+1.6%) | 38.71M +3.5M (+10.1%) | 8.99% +0.119 pp | 1.28% +0.059 pp | USD9.25 -28.1% | 10 qtrs — |
| 4 | BLACKROCK, INC. | 4.10M -381.4K (-8.5%) | 27.23M -253.1K (-0.9%) | 6.33% -0.609 pp | 0.00% +0.000 pp | USD15.39 -56.8% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 3.34M -87.1K (-2.5%) | 22.22M +1.2M (+5.6%) | 5.16% -0.150 pp | 0.00% +0.000 pp | USD12.16 -45.3% | 32 qtrs — |
| 6 | BRAIDWELL LP | 3.11M +3.1M (+100.0%) | 20.65M +20.6M (+100.0%) | 4.80% +4.798 pp | 0.66% +0.660 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 7 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 2.63M +— (+0.0%) | 17.49M +1.3M (+8.3%) | 4.06% -0.012 pp | 0.47% -0.014 pp | USD8.98 -25.9% | 3 qtrs — |
| 8 | MILLENNIUM MANAGEMENT LLC | 2.09M +234.0K (+12.6%) | 13.92M +2.5M (+21.9%) | 3.23% +0.353 pp | 0.01% +0.001 pp | USD8.95 -25.7% | 21 qtrs — |
| 9 | STONEPINE CAPITAL MANAGEMENT, LLC | 1.63M +95.2K (+6.2%) | 10.85M +1.4M (+15.0%) | 2.52% +0.140 pp | 7.92% +0.253 pp | USD7.01 -5.1% | 18 qtrs — |
| 10 | STATE STREET CORP | 1.57M +59.6K (+3.9%) | 10.47M +1.2M (+12.6%) | 2.43% +0.085 pp | 0.00% +0.000 pp | USD10.57 -37.1% | 32 qtrs — |
| 11 | D. E. SHAW & CO., INC. | 1.54M +186.7K (+13.8%) | 10.25M +1.9M (+23.2%) | 2.38% +0.282 pp | 0.01% +0.001 pp | USD9.47 -29.8% | 20 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.39M -30.9K (-2.2%) | 9.22M +518.4K (+6.0%) | 2.14% -0.054 pp | 0.00% +0.000 pp | USD11.03 -39.7% | 32 qtrs — |
| 13 | CITADEL ADVISORS LLC | 1.38M +790.7K (+134.4%) | 9.17M +5.6M (+153.9%) | 2.13% +1.219 pp | 0.00% +0.001 pp | USD8.31 -20.0% | 29 qtrs — |
| 14 | TANG CAPITAL MANAGEMENT LLC | 1.25M -4.2M (-77.3%) | 8.28M -25.4M (-75.4%) | 1.92% -6.579 pp | 0.41% -0.888 pp | USD9.54 -30.3% | 14 qtrs — |
| 15 | RICE HALL JAMES & ASSOCIATES, LLC | 1.15M -15.4K (-1.3%) | 7.67M +493.4K (+6.9%) | 1.78% -0.029 pp | 0.42% +0.031 pp | USD8.39 -20.7% | 12 qtrs — |
| 16 | SOLEUS CAPITAL MANAGEMENT, L.P. | 1.07M -380.0K (-26.2%) | 7.12M -1.8M (-20.1%) | 1.65% -0.594 pp | 0.26% -0.186 pp | USD10.46 -36.4% | 11 qtrs — |
| 17 | SCHRODER INVESTMENT MANAGEMENT GROUP | 986.5K -28.0K (-2.8%) | 6.58M +350.9K (+5.6%) | 1.52% -0.048 pp | 0.01% +0.000 pp | USD9.73 -31.7% | 25 qtrs — |
| 18 | ARMISTICE CAPITAL, LLC | 976.0K +976.0K (+100.0%) | 6.49M +6.5M (+100.0%) | 1.51% +1.508 pp | 0.08% +0.077 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 19 | UBS GROUP AG | 881.4K -148.7K (-14.4%) | 5.86M -463.8K (-7.3%) | 1.36% -0.234 pp | 0.00% +0.000 pp | USD9.12 -27.1% | 32 qtrs — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 799.9K +173.9K (+27.8%) | 5.32M +1.5M (+38.4%) | 1.24% +0.266 pp | 0.01% +0.003 pp | USD7.85 -15.3% | 4 qtrs — |
| 21 | PINNACLE ASSOCIATES LTD | 782.4K +107.5K (+15.9%) | 5.20M +1.1M (+25.6%) | 1.21% +0.163 pp | 0.07% +0.012 pp | USD8.86 -24.9% | 3 qtrs — |
| 22 | MORGAN STANLEY | 730.7K +464.9K (+175.0%) | 4.86M +3.2M (+197.8%) | 1.13% +0.717 pp | 0.00% +0.000 pp | USD8.08 -17.7% | 32 qtrs — |
| 23 | ECOR1 CAPITAL, LLC | 675.0K +675.0K (+100.0%) | 4.49M +4.5M (+100.0%) | 1.04% +1.043 pp | 0.20% +0.204 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 24 | SOVIERO ASSET MANAGEMENT, LP | 655.0K +325.0K (+98.5%) | 4.36M +2.3M (+115.0%) | 1.01% +0.501 pp | 2.09% +1.035 pp | USD6.39 +4.1% | 2 qtrs — |
| 25 | AWH CAPITAL, L.P. | 625.0K +— (+0.0%) | 4.16M +318.8K (+8.3%) | 0.97% -0.003 pp | 3.83% -0.169 pp | USD8.99 -26.0% | 21 qtrs — |
| 26 | BNP PARIBAS ARBITRAGE, SNC | 565.0K +493.5K (+689.8%) | 3.76M +3.3M (+755.4%) | 0.87% +0.762 pp | 0.00% +0.002 pp | USD7.22 -7.9% | 32 qtrs — |
| 27 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 517.1K +26.8K (+5.5%) | 3.44M +428.4K (+14.2%) | 0.80% +0.039 pp | 0.00% +0.000 pp | USD12.65 -47.4% | 31 qtrs — |
| 28 | NORTHERN TRUST CORP | 445.2K -107.2K (-19.4%) | 2.96M -431.4K (-12.7%) | 0.69% -0.168 pp | 0.00% 0.000 pp | USD11.69 -43.1% | 32 qtrs — |
| 29 | DEUTSCHE BANK AG\ | 436.7K +333.0 (+0.1%) | 2.90M +224.8K (+8.4%) | 0.67% -0.001 pp | 0.00% +0.000 pp | USD9.23 -28.0% | 32 qtrs — |
| 30 | HRT FINANCIAL LP | 428.6K +428.6K (+100.0%) | 2.85M +2.9M (+100.0%) | 0.66% +0.662 pp | 0.01% +0.009 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 31 | JANE STREET GROUP, LLC | 417.3K +144.0K (+52.7%) | 2.77M +1.1M (+65.4%) | 0.64% +0.221 pp | 0.00% +0.000 pp | USD7.33 -9.3% | 20 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 358.0K +91.9K (+34.5%) | 2.38M +747.1K (+45.7%) | 0.55% +0.141 pp | 0.00% +0.000 pp | USD8.42 -21.0% | 32 qtrs — |
| 33 | GOLDMAN SACHS GROUP INC | 350.7K -107.0K (-23.4%) | 2.33M -477.8K (-17.0%) | 0.54% -0.167 pp | 0.00% 0.000 pp | USD10.53 -36.8% | 32 qtrs — |
| 34 | EVERSEPT PARTNERS, LP | 344.1K -1.1M (-76.7%) | 2.29M -6.8M (-74.7%) | 0.53% -1.754 pp | 0.12% -0.509 pp | USD8.58 -22.5% | 7 qtrs — |
| 35 | CAMPBELL & CO INVESTMENT ADVISER LLC | 340.2K +320.7K (+1,641.6%) | 2.26M +2.1M (+1,786.3%) | 0.53% +0.495 pp | 0.11% +0.100 pp | USD6.80 -2.2% | 3 qtrs — |
| 36 | ASSENAGON ASSET MANAGEMENT S.A. | 270.2K -15.6K (-5.4%) | 1.80M +42.3K (+2.4%) | 0.42% -0.025 pp | 0.00% +0.000 pp | USD11.50 -42.2% | 8 qtrs — |
| 37 | STIFEL FINANCIAL CORP | 263.1K -14.8K (-5.3%) | 1.75M +43.4K (+2.5%) | 0.41% -0.024 pp | 0.00% +0.000 pp | USD9.63 -30.9% | 24 qtrs — |
| 38 | CM MANAGEMENT, LLC | 250.0K +— (+0.0%) | 1.66M +127.5K (+8.3%) | 0.39% -0.001 pp | 1.40% +0.122 pp | USD7.69 -13.5% | 11 qtrs — |
| 39 | JPMORGAN CHASE & CO | 225.6K -220.7K (-49.5%) | 1.50M -1.2M (-45.3%) | 0.35% -0.343 pp | 0.00% 0.000 pp | USD12.21 -45.5% | 32 qtrs — |
| 40 | WELLINGTON MANAGEMENT GROUP LLP | 195.2K +10.9K (+5.9%) | 1.30M +166.2K (+14.7%) | 0.30% +0.016 pp | 0.00% +0.000 pp | USD11.66 -43.0% | 9 qtrs — |
| 41 | SQUAREPOINT OPS LLC | 174.3K +133.1K (+323.0%) | 1.16M +906.4K (+358.2%) | 0.27% +0.206 pp | 0.00% +0.001 pp | USD7.27 -8.5% | 11 qtrs — |
| 42 | BANK OF NEW YORK MELLON CORP | 137.8K -5.0K (-3.5%) | 916.4K +39.4K (+4.5%) | 0.21% -0.008 pp | 0.00% +0.000 pp | USD11.89 -44.1% | 31 qtrs — |
| 43 | WALLEYE CAPITAL LLC | 133.0K +120.7K (+987.5%) | 884.3K +809.2K (+1,077.8%) | 0.21% +0.187 pp | 0.00% +0.002 pp | USD7.42 -10.4% | 11 qtrs — |
| 44 | BARCLAYS PLC | 130.7K +37.1K (+39.6%) | 869.4K -647.9K (-42.7%) | 0.20% +0.057 pp | 0.00% 0.000 pp | USD10.84 -38.7% | 32 qtrs — |
| 45 | AMERICAN ASSETS INC | 125.0K +— (+0.0%) | 831.3K +63.8K (+8.3%) | 0.19% -0.001 pp | 0.26% +0.017 pp | USD6.14 +8.3% | 2 qtrs — |
| 46 | DIADEMA PARTNERS LP | 118.8K +118.8K (+100.0%) | 790.0K +790.0K (+100.0%) | 0.18% +0.184 pp | 0.14% +0.136 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 47 | GSA CAPITAL PARTNERS LLP | 118.1K +118.1K (+100.0%) | 786.0K +786.0K (+100.0%) | 0.18% +0.183 pp | 0.07% +0.068 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 48 | TWO SIGMA INVESTMENTS, LP | 102.1K +82.3K (+416.4%) | 678.9K +557.5K (+459.3%) | 0.16% +0.127 pp | 0.00% +0.001 pp | USD7.66 -13.2% | 19 qtrs — |
| 49 | BOOTHBAY FUND MANAGEMENT, LLC | 101.8K -927.9K (-90.1%) | 677.1K -5.6M (-89.3%) | 0.16% -1.438 pp | 0.01% -0.082 pp | USD10.90 -39.0% | 20 qtrs — |
| 50 | KRENSAVAGE ASSET MANAGEMENT, LLC | 100.0K +— (+0.0%) | 665.0K +51.0K (+8.3%) | 0.15% 0.000 pp | 0.23% -0.027 pp | USD6.14 +8.3% | 2 qtrs — |
| 51 | KNOTT DAVID M JR | 99.3K +99.3K (+100.0%) | 660.6K +660.6K (+100.0%) | 0.15% +0.154 pp | 0.31% +0.306 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 52 | QUANTINNO CAPITAL MANAGEMENT LP | 89.0K +56.5K (+173.6%) | 591.8K +392.0K (+196.3%) | 0.14% +0.087 pp | 0.00% +0.001 pp | USD7.03 -5.4% | 3 qtrs — |
| 53 | NUVEEN, LLC | 88.4K -983.0K (-91.8%) | 587.7K -6.0M (-91.1%) | 0.14% -1.524 pp | 0.00% -0.002 pp | USD11.07 -39.9% | 4 qtrs — |
| 54 | PRICE T ROWE ASSOCIATES INC /MD/ | 85.4K +22.0K (+34.8%) | 568.0K +179.0K (+46.0%) | 0.13% +0.034 pp | 0.00% +0.000 pp | USD8.90 -25.3% | 20 qtrs — |
| 55 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 80.2K +3.3K (+4.3%) | 533.0K +61.3K (+13.0%) | 0.12% +0.005 pp | 0.00% +0.000 pp | USD12.32 -46.0% | 14 qtrs — |
| 56 | MAREX GROUP PLC | 76.9K +30.0K (+64.0%) | 511.1K +223.4K (+77.7%) | 0.12% +0.046 pp | 0.00% +0.001 pp | USD6.34 +4.9% | 2 qtrs — |
| 57 | WELLS FARGO & COMPANY/MN | 76.0K +27.8K (+57.8%) | 505.2K +209.5K (+70.9%) | 0.12% +0.043 pp | 0.00% +0.000 pp | USD9.20 -27.7% | 32 qtrs — |
| 58 | RHUMBLINE ADVISERS | 70.0K -12.7K (-15.3%) | 465.8K -42.1K (-8.3%) | 0.11% -0.020 pp | 0.00% +0.000 pp | USD10.04 -33.8% | 29 qtrs — |
| 59 | XTX TOPCO LTD | 68.0K -72.8K (-51.7%) | 452.1K -412.2K (-47.7%) | 0.11% -0.113 pp | 0.01% -0.033 pp | USD9.17 -27.5% | 4 qtrs — |
| 60 | RUSSELL INVESTMENTS GROUP, LTD. | 65.6K -668.0 (-1.0%) | 436.0K +29.3K (+7.2%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD7.45 -10.7% | 22 qtrs — |
| 61 | STATE OF WISCONSIN INVESTMENT BOARD | 65.1K -23.1K (-26.2%) | 432.9K -108.5K (-20.0%) | 0.10% -0.036 pp | 0.00% 0.000 pp | USD11.33 -41.3% | 19 qtrs — |
| 62 | ALLIANCEBERNSTEIN L.P. | 62.3K +— (+0.0%) | 414.6K +31.8K (+8.3%) | 0.10% 0.000 pp | 0.00% +0.000 pp | USD11.40 -41.7% | 31 qtrs — |
| 63 | SKOPOS LABS, INC. | 61.7K +61.7K (+100.0%) | 411.2K +411.2K (+100.0%) | 0.10% +0.095 pp | 0.02% +0.019 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 64 | LPL FINANCIAL LLC | 61.0K -13.9K (-18.6%) | 405.5K -54.5K (-11.8%) | 0.09% -0.022 pp | 0.00% +0.000 pp | USD6.85 -2.9% | 28 qtrs — |
| 65 | AMERIPRISE FINANCIAL INC | 54.3K -3.1K (-5.3%) | 360.9K +8.9K (+2.5%) | 0.08% -0.005 pp | 0.00% +0.000 pp | USD11.79 -43.6% | 28 qtrs — |
| 66 | GWN SECURITIES INC. | 48.9K +48.9K (+100.0%) | 325.3K +325.3K (+100.0%) | 0.08% +0.076 pp | 0.07% +0.066 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 67 | SEI INVESTMENTS CO | 45.5K -2.8K (-5.9%) | 302.6K +5.8K (+2.0%) | 0.07% -0.005 pp | 0.00% +0.000 pp | USD12.21 -45.5% | 23 qtrs — |
| 68 | MAN GROUP PLC | 43.4K -39.6K (-47.7%) | 288.6K -220.7K (-43.3%) | 0.07% -0.062 pp | 0.00% 0.000 pp | USD11.41 -41.7% | 5 qtrs — |
| 69 | INTEGRATED QUANTITATIVE INVESTMENTS LLC | 42.0K +42.0K (+100.0%) | 279.1K +279.1K (+100.0%) | 0.06% +0.065 pp | 0.06% +0.060 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 70 | PATHSTONE HOLDINGS, LLC | 41.1K +13.8K (+50.6%) | 273.0K +105.7K (+63.1%) | 0.06% +0.021 pp | 0.00% +0.000 pp | USD8.35 -20.4% | 3 qtrs — |
| 71 | PRELUDE CAPITAL MANAGEMENT, LLC | 39.3K +4.0K (+11.4%) | 261.4K +44.8K (+20.7%) | 0.06% +0.006 pp | 0.02% +0.002 pp | USD6.19 +7.4% | 2 qtrs — |
| 72 | ADAR1 CAPITAL MANAGEMENT, LLC | 35.9K +35.9K (+100.0%) | 238.5K +238.5K (+100.0%) | 0.06% +0.055 pp | 0.02% +0.018 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 73 | CITIGROUP INC | 35.5K +13.6K (+62.1%) | 235.9K +101.5K (+75.6%) | 0.05% +0.021 pp | 0.00% +0.000 pp | USD10.57 -37.1% | 32 qtrs — |
| 74 | INVESCO LTD. | 34.1K +451.0 (+1.3%) | 226.9K +20.2K (+9.8%) | 0.05% +0.001 pp | 0.00% +0.000 pp | USD13.70 -51.5% | 20 qtrs — |
| 75 | INTECH INVESTMENT MANAGEMENT LLC | 32.7K +2.3K (+7.6%) | 217.4K +30.8K (+16.5%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD12.23 -45.6% | 6 qtrs — |
| 76 | FOX RUN MANAGEMENT, L.L.C. | 32.7K +5.5K (+20.1%) | 217.2K +50.2K (+30.0%) | 0.05% +0.008 pp | 0.03% +0.008 pp | USD6.23 +6.7% | 2 qtrs — |
| 77 | ATOM INVESTORS LP | 32.5K +32.5K (+100.0%) | 216.1K +216.1K (+100.0%) | 0.05% +0.050 pp | 0.02% +0.017 pp | USD6.65 +0.0% | 3 qtrs — |
| 78 | METLIFE INVESTMENT MANAGEMENT, LLC | 28.4K +2.3K (+8.6%) | 188.8K +28.3K (+17.7%) | 0.04% +0.003 pp | 0.00% +0.000 pp | USD10.87 -38.8% | 19 qtrs — |
| 79 | AQUATIC CAPITAL MANAGEMENT LLC | 28.4K +20.5K (+259.5%) | 188.7K +140.3K (+289.4%) | 0.04% +0.032 pp | 0.01% +0.005 pp | USD6.51 +2.2% | 11 qtrs — |
| 80 | SG AMERICAS SECURITIES, LLC | 27.8K +27.8K (+100.0%) | 185.0K +185.0K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD6.65 +0.0% | 14 qtrs — |
| 81 | VERSOR INVESTMENTS LP | 26.7K +26.7K (+100.0%) | 177.6K +177.6K (+100.0%) | 0.04% +0.041 pp | 0.03% +0.028 pp | USD6.65 +0.0% | 3 qtrs — |
| 82 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 26.2K -7.9K (-23.1%) | 174.3K -34.9K (-16.7%) | 0.04% -0.012 pp | 0.00% -0.001 pp | USD10.56 -37.0% | 5 qtrs — |
| 83 | ALPINE GLOBAL MANAGEMENT, LLC | 26.1K +26.1K (+100.0%) | 173.5K +173.5K (+100.0%) | 0.04% +0.040 pp | 0.03% +0.031 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 84 | SIMPLEX TRADING, LLC | 24.7K +19.3K (+358.0%) | 164.1K +131.1K (+397.4%) | 0.04% +0.030 pp | 0.00% +0.000 pp | USD7.44 -10.6% | 20 qtrs — |
| 85 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 24.1K -3.1K (-11.4%) | 160.4K -6.8K (-4.1%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD12.55 -47.0% | 7 qtrs — |
| 86 | CREATIVE PLANNING | 24.1K +1.5K (+6.7%) | 160.0K +21.5K (+15.6%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD6.17 +7.8% | 7 qtrs — |
| 87 | AQR CAPITAL MANAGEMENT LLC | 23.0K -35.4K (-60.6%) | 152.8K -205.4K (-57.3%) | 0.04% -0.055 pp | 0.00% 0.000 pp | USD12.47 -46.7% | 19 qtrs — |
| 88 | OXFORD ASSET MANAGEMENT LLP | 22.9K +22.9K (+100.0%) | 152.4K +152.4K (+100.0%) | 0.04% +0.035 pp | 0.06% +0.062 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 89 | VIRTU FINANCIAL LLC | 22.7K +22.7K (+100.0%) | 151.0K +151.0K (+100.0%) | 0.04% +0.035 pp | 0.01% +0.006 pp | USD6.65 +0.0% | 3 qtrs — |
| 90 | MERCER GLOBAL ADVISORS INC /ADV | 21.7K +21.7K (+100.0%) | 144.0K +144.0K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 91 | PROFUND ADVISORS LLC | 20.4K +2.3K (+12.7%) | 135.8K +24.5K (+22.0%) | 0.03% +0.004 pp | 0.00% +0.001 pp | USD7.83 -15.1% | 7 qtrs — |
| 92 | TWO SIGMA ADVISERS, LP | 19.4K -7.1K (-26.8%) | 129.0K -33.7K (-20.7%) | 0.03% -0.011 pp | 0.00% 0.000 pp | USD12.01 -44.6% | 4 qtrs — |
| 93 | TREXQUANT INVESTMENT LP | 18.8K +18.8K (+100.0%) | 125.3K +125.3K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.001 pp | USD6.65 +0.0% | 18 qtrs — |
| 94 | RAFFERTY ASSET MANAGEMENT, LLC | 18.2K +5.7K (+45.4%) | 120.9K +44.1K (+57.5%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD6.30 +5.6% | 2 qtrs — |
| 95 | QUADRATURE CAPITAL LTD | 18.1K +4.2K (+29.9%) | 120.3K +34.6K (+40.4%) | 0.03% +0.006 pp | 0.00% +0.000 pp | USD6.26 +6.2% | 2 qtrs — |
| 96 | PURE FINANCIAL ADVISORS, LLC | 17.8K -34.0 (-0.2%) | 118.4K +8.9K (+8.1%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD6.14 +8.3% | 2 qtrs — |
| 97 | ENVESTNET ASSET MANAGEMENT INC | 16.7K +16.7K (+100.0%) | 111.1K +111.1K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD6.65 +0.0% | 1 qtrs NEW |
| 98 | QUEST PARTNERS LLC | 16.4K +— (+0.0%) | 109.1K +8.4K (+8.3%) | 0.03% 0.000 pp | 0.01% -0.001 pp | USD8.70 -23.6% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 62 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 0.49% | 2.33M | 0.35% |
| 2 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.10% | 23.9K | 1.22% |
| 3 | iShares U.S. Pharmaceuticals ETF IHE | 0.10% | 1.32M | 0.38% |
| 4 | iShares Micro-Cap ETF IWC | 0.09% | 1.32M | 0.60% |
| 5 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.06% | 644.0K | 0.20% |
| 6 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 138.7K | 0.40% |
| 7 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 22.4K | 0.19% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 20.7K | 0.35% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 309.0K | 0.35% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.02% | 3.70M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.67
Bullish
Ratio by volume
3.00
Bullish
Buys
16
Sells
6
Shares acquired
2.45M
Shares disposed
239.8K
Cash buys
—
Cash sales
4.00
Net activity
+2,210,392
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 13,669 | 4.75 | 64.9K | 604,700 | D | ↗ |
| 2026-03-20 | Avelar Rui | Officer | S-Sale | D | Common Stock | 3,119 | 4.75 | 14.8K | 427,423 | D | ↗ |
| 2026-03-17 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 116,720 | 4.89 | 570.6K | 618,369 | D | ↗ |
| 2026-03-17 | Avelar Rui | Officer | S-Sale | D | Common Stock | 29,996 | 4.89 | 146.6K | 430,542 | D | ↗ |
| 2026-03-16 | MOATAZEDI DAVID | Director / Officer | M-Exempt | A | Common Stock | 67,489 | 0.00 | — | 735,089 | D | ↗ |
| 2026-03-16 | Avelar Rui | Officer | M-Exempt | A | Common Stock | 8,804 | 0.00 | — | 460,538 | D | ↗ |
| 2026-02-17 | White Albert G III | Director | A-Award | A | Common Stock | 45,559 | 0.00 | — | 95,937 | D | ↗ |
| 2026-02-17 | Stewart Brady | Director | A-Award | A | Common Stock | 45,559 | 0.00 | — | 134,188 | D | ↗ |
| 2026-02-17 | Parschauer Karah Herdman | Director | A-Award | A | Common Stock | 45,559 | 0.00 | — | 77,742 | D | ↗ |
| 2026-02-17 | Mitchell Tatjana | Officer | A-Award | A | Stock Option (Right to Buy) | 177,471 | 4.39 | 779.1K | 177,471 | D | ↗ |
| 2026-02-17 | Malik Vikram | Director | A-Award | A | Common Stock | 45,559 | 0.00 | — | 321,109 | D | ↗ |
| 2026-02-17 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Performance Restricted Stock Units | 626,424 | 0.00 | — | 626,424 | D | ↗ |
| 2026-02-17 | GILL DAVID N | Director | A-Award | A | Common Stock | 45,559 | 0.00 | — | 86,887 | D | ↗ |
| 2026-02-17 | Avelar Rui | Officer | A-Award | A | Performance Restricted Stock Units | 94,913 | 0.00 | — | 94,913 | D | ↗ |
| 2025-12-22 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 10,539 | 7.15 | 75.4K | 354,388 | D | ↗ |
| 2025-12-22 | Avelar Rui | Officer | S-Sale | D | Common Stock | 2,261 | 7.15 | 16.2K | 356,821 | D | ↗ |
| 2025-09-08 | Mitchell Tatjana | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-22 | Yamagishi-Dressler Tomoko | Officer | S-Sale | D | Common Stock | 5,722 | 7.51 | 43.0K | 89,949 | D | ↗ |
| 2025-08-15 | Stewart Brady | Director | P-Purchase | A | Common Stock | 30,000 | 6.82 | 204.5K | 88,629 | D | ↗ |
| 2025-06-16 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 16,582 | 9.89 | 164.1K | 364,927 | D | ↗ |
| 2025-06-13 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 111,323 | 10.05 | 1.12M | 381,509 | D | ↗ |
| 2025-06-09 | White Albert G III | Director | P-Purchase | A | Common Stock | 20,000 | 9.45 | 189.0K | 50,378 | D | ↗ |
| 2025-05-13 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 6,494 | 10.02 | 65.1K | 167,089 | D | ↗ |
| 2025-05-12 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 15,787 | 9.87 | 155.8K | 492,832 | D | ↗ |
| 2025-05-12 | Avelar Rui | Officer | S-Sale | D | Common Stock | 3,385 | 9.87 | 33.4K | 359,082 | D | ↗ |
| 2025-03-27 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 6,251 | 12.40 | 77.5K | 508,619 | D | ↗ |
| 2025-03-18 | Yamagishi-Dressler Tomoko | Officer | S-Sale | D | Common Stock | 4,536 | 13.26 | 60.1K | 95,671 | D | ↗ |
| 2025-03-18 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 103,376 | 13.26 | 1.37M | 514,870 | D | ↗ |
| 2025-03-18 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 8,996 | 13.26 | 119.2K | 173,583 | D | ↗ |
| 2025-03-18 | Avelar Rui | Officer | S-Sale | D | Common Stock | 27,904 | 13.26 | 369.9K | 362,467 | D | ↗ |
| 2025-03-12 | Parschauer Karah Herdman | Director | S-Sale | D | Common Stock | 12,888 | 12.99 | 167.5K | 32,183 | D | ↗ |
| 2025-03-07 | Yamagishi-Dressler Tomoko | Officer | A-Award | A | Performance Restricted Stock Units | 17,832 | 0.00 | — | 17,832 | D | ↗ |
| 2025-03-07 | White Albert G III | Director | A-Award | A | Common Stock | 7,364 | 0.00 | — | 30,378 | D | ↗ |
| 2025-03-07 | Stewart Brady | Director | A-Award | A | Common Stock | 7,364 | 0.00 | — | 58,629 | D | ↗ |
| 2025-03-07 | Parschauer Karah Herdman | Director | A-Award | A | Common Stock | 7,364 | 0.00 | — | 45,071 | D | ↗ |
| 2025-03-07 | Malik Vikram | Director | A-Award | A | Common Stock | 7,364 | 0.00 | — | 253,878 | D | ↗ |
| 2025-03-07 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Common Stock | 95,399 | 0.00 | — | 618,246 | D | ↗ |
| 2025-03-07 | GILL DAVID N | Director | A-Award | A | Common Stock | 7,364 | 0.00 | — | 41,328 | D | ↗ |
| 2025-03-07 | Beaver Sandra | Officer | A-Award | A | Performance Restricted Stock Units | 35,663 | 0.00 | — | 35,663 | D | ↗ |
| 2025-03-07 | BLANK SIMONE | Director | A-Award | A | Common Stock | 7,364 | 0.00 | — | 77,111 | D | ↗ |
| 2025-03-07 | Avelar Rui | Officer | A-Award | A | Performance Restricted Stock Units | 23,776 | 0.00 | — | 23,776 | D | ↗ |
| 2024-12-23 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 10,502 | 10.85 | 114.0K | 522,847 | D | ↗ |
| 2024-12-23 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 1,586 | 10.85 | 17.2K | 146,916 | D | ↗ |
| 2024-12-23 | Avelar Rui | Officer | S-Sale | D | Common Stock | 2,252 | 10.85 | 24.4K | 366,595 | D | ↗ |
| 2024-09-06 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 3,276 | 14.98 | 49.1K | 148,502 | — | ↗ |
| 2024-08-30 | Yamagishi-Dressler Tomoko | Officer | S-Sale | D | Common Stock | 5,631 | 15.85 | 89.3K | 82,375 | — | ↗ |
| 2024-07-01 | White Albert G III | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-06 | MOATAZEDI DAVID | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 175,940 | 7.28 | 1.28M | 1,006,079 | — | ↗ |
| 2024-06-05 | MOATAZEDI DAVID | Director / Officer | M-Exempt | A | Common Stock | 155,278 | 5.46 | 847.8K | 688,627 | — | ↗ |
| 2024-06-04 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 140,214 | 12.73 | 1.78M | 533,349 | — | ↗ |
| 2024-06-03 | Malik Vikram | Director | S-Sale | D | Common Stock | 7,500 | 12.96 | 97.2K | 246,514 | — | ↗ |
| 2024-05-14 | GILL DAVID N | Director | S-Sale | D | Common Stock | 6,718 | 12.60 | 84.7K | 33,964 | — | ↗ |
| 2024-05-13 | Malik Vikram | Director | S-Sale | D | Common Stock | 28,000 | 12.93 | 362.0K | 254,014 | — | ↗ |
| 2024-05-13 | GILL DAVID N | Director | S-Sale | D | Common Stock | 3,643 | 12.72 | 46.4K | 40,682 | — | ↗ |
| 2024-05-10 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 16,051 | 12.72 | 204.1K | 673,563 | — | ↗ |
| 2024-05-10 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 2,423 | 12.72 | 30.8K | 151,778 | — | ↗ |
| 2024-05-10 | Avelar Rui | Officer | S-Sale | D | Common Stock | 3,441 | 12.72 | 43.8K | 368,847 | — | ↗ |
| 2024-03-27 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 6,236 | 13.86 | 86.4K | 689,614 | — | ↗ |
| 2024-03-19 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 96,566 | 13.92 | 1.34M | 695,850 | — | ↗ |
| 2024-03-19 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 5,672 | 13.92 | 79.0K | 154,201 | — | ↗ |
| 2024-03-19 | Avelar Rui | Officer | S-Sale | D | Common Stock | 27,603 | 13.92 | 384.3K | 372,288 | — | ↗ |
| 2024-02-22 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 7,706 | 13.08 | 100.8K | 792,416 | — | ↗ |
| 2024-02-22 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 1,821 | 13.08 | 23.8K | 159,873 | — | ↗ |
| 2024-02-22 | Avelar Rui | Officer | S-Sale | D | Common Stock | 1,821 | 13.08 | 23.8K | 399,891 | — | ↗ |
| 2024-02-21 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Common Stock | 61,202 | 0.00 | — | 800,122 | — | ↗ |
| 2024-02-21 | Beaver Sandra | Officer | A-Award | A | Common Stock | 13,115 | 0.00 | — | 161,694 | — | ↗ |
| 2024-02-21 | Avelar Rui | Officer | A-Award | A | Common Stock | 13,115 | 0.00 | — | 401,712 | — | ↗ |
| 2024-02-07 | Yamagishi-Dressler Tomoko | Officer | A-Award | A | Performance Restricted Stock Units | 12,324 | 0.00 | — | 12,324 | — | ↗ |
| 2024-02-07 | Stewart Brady | Director | A-Award | A | Stock Option (Right to Buy) | 9,377 | 13.15 | 123.3K | 9,377 | — | ↗ |
| 2024-02-07 | Parschauer Karah Herdman | Director | A-Award | A | Common Stock | 6,464 | 0.00 | — | 37,707 | — | ↗ |
| 2024-02-07 | Malik Vikram | Director | A-Award | A | Stock Option (Right to Buy) | 9,377 | 13.15 | 123.3K | 9,377 | — | ↗ |
| 2024-02-07 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 181,460 | 13.15 | 2.39M | 181,460 | — | ↗ |
| 2024-02-07 | HAYMAN ROBERT | Director | A-Award | A | Common Stock | 6,464 | 0.00 | — | 54,856 | — | ↗ |
| 2024-02-07 | GILL DAVID N | Director | A-Award | A | Common Stock | 6,464 | 0.00 | — | 44,325 | — | ↗ |
| 2024-02-07 | Beaver Sandra | Officer | A-Award | A | Common Stock | 35,211 | 0.00 | — | 148,579 | — | ↗ |
| 2024-02-07 | BLANK SIMONE | Director | A-Award | A | Stock Option (Right to Buy) | 9,377 | 13.15 | 123.3K | 9,377 | — | ↗ |
| 2024-02-07 | Avelar Rui | Officer | A-Award | A | Common Stock | 35,211 | 0.00 | — | 388,597 | — | ↗ |
| 2024-01-30 | Parschauer Karah Herdman | Director | S-Sale | D | Common Stock | 11,931 | 13.14 | 156.7K | 31,243 | — | ↗ |
| 2023-12-08 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 31,300 | 9.73 | 304.5K | 603,944 | — | ↗ |
| 2023-12-06 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 51,348 | 10.09 | 517.9K | 635,244 | — | ↗ |
| 2023-10-16 | Medytox Inc. | — | S-Sale | D | Common Stock, $0.00001 par value per share | 1,690,663 | 7.50 | 12.68M | 3,381,326 | — | ↗ |
| 2023-09-06 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 3,178 | 9.70 | 30.8K | 113,368 | — | ↗ |
| 2023-08-21 | Yamagishi-Dressler Tomoko | Officer | A-Award | A | Stock Option (Right to Buy) | 83,555 | 9.40 | 785.4K | 83,555 | — | ↗ |
| 2023-08-16 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 14,778 | 10.27 | 151.8K | 686,592 | — | ↗ |
| 2023-08-16 | Beaver Sandra | Officer | S-Sale | D | Common Stock | 2,211 | 10.27 | 22.7K | 116,546 | — | ↗ |
| 2023-08-16 | Avelar Rui | Officer | S-Sale | D | Common Stock | 2,211 | 10.27 | 22.7K | 353,386 | — | ↗ |
| 2023-08-15 | Malik Vikram | Director | P-Purchase | A | Common Stock | 174,967 | 7.41 | 1.30M | 275,550 | — | ↗ |
| 2023-08-14 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Common Stock | 91,803 | 0.00 | — | 701,370 | — | ↗ |
| 2023-08-14 | Beaver Sandra | Officer | A-Award | A | Common Stock | 19,672 | 0.00 | — | 118,757 | — | ↗ |
| 2023-08-14 | Avelar Rui | Officer | A-Award | A | Common Stock | 19,672 | 0.00 | — | 355,597 | — | ↗ |
| 2023-08-11 | Malik Vikram | Director | J-Other | A | Common Stock | 22,998 | 0.00 | — | 100,583 | — | ↗ |
| 2023-08-11 | HAYMAN ROBERT | Director | J-Other | A | Common Stock | 218 | 0.00 | — | 48,392 | — | ↗ |
| 2023-08-11 | BLANK SIMONE | Director | J-Other | A | Common Stock | 115,206 | 0.00 | — | 482,783 | — | ↗ |
| 2023-05-08 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Restricted Stock Units | 560,000 | 0.00 | — | 560,000 | — | ↗ |
| 2023-03-27 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 6,110 | 8.47 | 51.8K | 609,567 | — | ↗ |
| 2023-03-14 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 64,211 | 8.47 | 543.8K | 615,677 | — | ↗ |
| 2023-03-14 | Avelar Rui | Officer | S-Sale | D | Common Stock | 14,906 | 8.47 | 126.2K | 335,925 | — | ↗ |
| 2023-02-17 | Alphaeon 1 LLC | 10% Owner | S-Sale | D | Class A Common Stock | 1,850,000 | 8.40 | 15.54M | 4,214,871 | — | ↗ |
| 2023-02-07 | Medytox Inc. | 10% Owner | S-Sale | D | Common Stock, $0.00001 par value per share | 2,187,511 | 8.50 | 18.59M | 5,071,989 | — | ↗ |
| 2023-01-27 | Stewart Brady | Director | A-Award | A | Stock Option (Right to Buy) | 11,789 | 10.25 | 120.8K | 11,789 | — | ↗ |
| 2023-01-27 | Parschauer Karah Herdman | Director | A-Award | A | Common Stock | 8,293 | 0.00 | — | 43,174 | — | ↗ |
| 2023-01-27 | Malik Vikram | Director | A-Award | A | Stock Option (Right to Buy) | 11,789 | 10.25 | 120.8K | 11,789 | — | ↗ |
| 2023-01-27 | HAYMAN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 11,789 | 10.25 | 120.8K | 11,789 | — | ↗ |
| 2023-01-27 | GILL DAVID N | Director | A-Award | A | Stock Option (Right to Buy) | 11,789 | 10.25 | 120.8K | 11,789 | — | ↗ |
| 2023-01-27 | FARRELL PETER C | Director | A-Award | A | Stock Option (Right to Buy) | 11,789 | 10.25 | 120.8K | 11,789 | — | ↗ |
| 2023-01-27 | BLANK SIMONE | Director | A-Award | A | Stock Option (Right to Buy) | 11,789 | 10.25 | 120.8K | 11,789 | — | ↗ |
| 2023-01-25 | MOATAZEDI DAVID | Officer | A-Award | A | Common Stock | 187,927 | 0.00 | — | 679,888 | — | ↗ |
| 2023-01-25 | Beaver Sandra | Officer | A-Award | A | Stock Option (Right to Buy) | 85,670 | 0.00 | — | 85,670 | — | ↗ |
| 2023-01-25 | Avelar Rui | Officer | A-Award | A | Stock Option (Right to Buy) | 85,670 | 0.00 | — | 85,670 | — | ↗ |
| 2023-01-20 | Medytox Inc. | 10% Owner | S-Sale | D | Common Stock, $0.00001 par value per share | 37,043 | 11.04 | 409.0K | 7,259,500 | — | ↗ |
| 2022-10-06 | Medytox Inc. | Director | S-Sale | D | Common Stock, $0.00001 par value per share | 38,304 | 8.99 | 344.4K | 7,259,500 | — | ↗ |
| 2022-10-05 | Medytox Inc. | Director | S-Sale | D | Common Stock, $0.00001 par value per share | 6,848 | 8.95 | 61.3K | 7,297,804 | — | ↗ |
| 2022-09-15 | Medytox Inc. | 10% Owner | S-Sale | D | Common Stock, $0.00001 par value per share | 24,000 | 10.34 | 248.1K | 7,304,652 | — | ↗ |
| 2022-09-14 | Medytox Inc. | 10% Owner | S-Sale | D | Common Stock, $0.00001 par value per share | 73,000 | 10.27 | 749.7K | 7,328,652 | — | ↗ |
| 2022-09-12 | HAYMAN ROBERT | Director | P-Purchase | A | Common Stock | 1,091 | 10.78 | 11.8K | 10,000 | — | ↗ |
| 2022-09-09 | HAYMAN ROBERT | Director | P-Purchase | A | Common Stock | 8,909 | 10.35 | 92.2K | 8,909 | — | ↗ |
| 2022-09-08 | Medytox Inc. | Director | S-Sale | D | Common Stock, $0.00001 par value per share | 20,700 | 10.53 | 217.9K | 7,401,652 | — | ↗ |
| 2022-09-07 | HAYMAN ROBERT | Director | P-Purchase | A | Common Stock | 4,967 | 10.05 | 49.9K | 39,848 | — | ↗ |
| 2022-09-06 | FARRELL PETER C | Director | P-Purchase | A | Common Stock | 10,000 | 9.10 | 91.0K | 10,000 | — | ↗ |
| 2022-09-06 | BLANK SIMONE | Director | P-Purchase | A | Common Stock | 20,000 | 9.24 | 184.8K | 54,881 | — | ↗ |
| 2022-09-05 | Beaver Sandra | Officer | A-Award | A | Common Stock | 36,443 | 0.00 | — | 36,443 | — | ↗ |
| 2022-08-01 | Medytox Inc. | Director | S-Sale | D | Common Stock, $0.00001 par value per share | 26,000 | 13.28 | 345.4K | 7,437,652 | — | ↗ |
| 2022-05-17 | SILVERNAIL LAUREN P | Officer | S-Sale | D | Common Stock | 16,189 | 13.92 | 225.4K | 193,586 | — | ↗ |
| 2022-05-16 | MOATAZEDI DAVID | Officer | S-Sale | D | Common Stock | 55,321 | 13.64 | 754.3K | 491,961 | — | ↗ |
| 2022-05-13 | GILL DAVID N | Director | S-Sale | D | Common Stock | 5,313 | 13.10 | 69.6K | 34,568 | — | ↗ |
| 2022-03-28 | MOATAZEDI DAVID | Officer | S-Sale | D | Common Stock | 6,104 | 11.62 | 70.9K | 547,282 | — | ↗ |
| 2022-03-08 | SILVERNAIL LAUREN P | Officer | S-Sale | D | Common Stock | 10,192 | 9.73 | 99.1K | 209,775 | — | ↗ |
| 2022-03-08 | Muilenburg Crystal | Officer | S-Sale | D | Common Stock | 6,495 | 9.73 | 63.2K | 134,248 | — | ↗ |
| 2022-03-08 | MOATAZEDI DAVID | Officer | S-Sale | D | Common Stock | 37,972 | 9.73 | 369.3K | 553,386 | — | ↗ |
| 2022-03-08 | Avelar Rui | Officer | S-Sale | D | Common Stock | 10,192 | 9.73 | 99.1K | 253,189 | — | ↗ |
| 2022-01-24 | SILVERNAIL LAUREN P | Officer | A-Award | A | Stock Option (Right to Buy) | 77,640 | 5.46 | 423.9K | 77,640 | — | ↗ |
| 2022-01-24 | Parschauer Karah Herdman | Director | A-Award | A | Stock Option (Right to Buy) | 22,727 | 5.46 | 124.1K | 22,727 | — | ↗ |
| 2022-01-24 | Muilenburg Crystal | Officer | A-Award | A | Stock Option (Right to Buy) | 72,464 | 5.46 | 395.7K | 72,464 | — | ↗ |
| 2022-01-24 | Malik Vikram | Director | A-Award | A | Stock Option (Right to Buy) | 22,727 | 5.46 | 124.1K | 22,727 | — | ↗ |
| 2022-01-24 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 310,559 | 5.46 | 1.70M | 310,559 | — | ↗ |
| 2022-01-24 | HAYMAN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 22,727 | 5.46 | 124.1K | 22,727 | — | ↗ |
| 2022-01-24 | GILL DAVID N | Director | A-Award | A | Stock Option (Right to Buy) | 22,727 | 5.46 | 124.1K | 22,727 | — | ↗ |
| 2022-01-24 | FARRELL PETER C | Director | A-Award | A | Stock Option (Right to Buy) | 22,727 | 5.46 | 124.1K | 22,727 | — | ↗ |
| 2022-01-24 | BLANK SIMONE | Director | A-Award | A | Stock Option (Right to Buy) | 22,727 | 5.46 | 124.1K | 22,727 | — | ↗ |
| 2022-01-24 | Avelar Rui | Officer | A-Award | A | Stock Option (Right to Buy) | 77,640 | 5.46 | 423.9K | 77,640 | — | ↗ |
| 2022-01-05 | Stewart Brady | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-09-02 | Alphaeon 1 LLC | 10% Owner | S-Sale | D | Common Stock | 2,597,475 | 9.50 | 24.68M | 6,064,871 | — | ↗ |
| 2021-08-27 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 51,000 | 10.93 | 557.6K | 7,463,652 | — | ↗ |
| 2021-08-26 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 66,000 | 11.02 | 727.4K | 7,412,652 | — | ↗ |
| 2021-08-25 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 44,000 | 11.12 | 489.4K | 7,346,652 | — | ↗ |
| 2021-08-24 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 72,219 | 11.17 | 807.0K | 7,302,652 | — | ↗ |
| 2021-08-23 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 69,781 | 11.03 | 769.8K | 7,230,433 | — | ↗ |
| 2021-08-23 | Malik Vikram | Director | S-Sale | D | Common Stock | 26,077 | 11.00 | 286.7K | 1,143,701 | — | ↗ |
| 2021-08-20 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 48,000 | 10.56 | 506.7K | 7,160,652 | — | ↗ |
| 2021-08-20 | Malik Vikram | Director | S-Sale | D | Common Stock | 49,878 | 10.61 | 529.3K | 1,169,778 | — | ↗ |
| 2021-08-19 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 55,000 | 10.51 | 578.1K | 7,112,652 | — | ↗ |
| 2021-08-19 | Malik Vikram | Director | S-Sale | D | Common Stock | 11,962 | 10.50 | 125.6K | 1,219,656 | — | ↗ |
| 2021-08-18 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 45,000 | 10.54 | 474.1K | 7,057,652 | — | ↗ |
| 2021-08-18 | Malik Vikram | Director | S-Sale | D | Common Stock | 25,000 | 10.44 | 261.0K | 1,231,618 | — | ↗ |
| 2021-08-17 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 70,000 | 10.69 | 748.1K | 7,012,652 | — | ↗ |
| 2021-08-17 | Malik Vikram | Director | S-Sale | D | Common Stock | 42,083 | 10.06 | 423.5K | 1,256,618 | — | ↗ |
| 2021-08-16 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 65,000 | 11.34 | 737.0K | 6,942,652 | — | ↗ |
| 2021-08-16 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 47,737 | 11.35 | 541.7K | 377,072 | — | ↗ |
| 2021-08-13 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 49,714 | 10.98 | 545.7K | 6,877,652 | — | ↗ |
| 2021-08-13 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 22,708 | 10.66 | 242.1K | 424,809 | — | ↗ |
| 2021-08-12 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 23,000 | 10.99 | 252.8K | 7,282,500 | — | ↗ |
| 2021-08-11 | Medytox Inc. | 10% Owner | P-Purchase | A | Common Stock, $0.00001 par value per share | 26,160 | 10.77 | 281.7K | 6,788,812 | — | ↗ |
| 2021-08-10 | SILVERNAIL LAUREN P | Officer | S-Sale | A | Common Stock | 14,293 | 11.18 | 159.8K | 194,982 | — | ↗ |
| 2021-08-10 | Muilenburg Crystal | Officer | S-Sale | A | Common Stock | 5,362 | 11.18 | 59.9K | 101,467 | — | ↗ |
| 2021-08-10 | MOATAZEDI DAVID | Director / Officer | S-Sale | A | Common Stock | 41,763 | 11.18 | 466.8K | 531,043 | — | ↗ |
| 2021-08-10 | Avelar Rui | Officer | S-Sale | D | Common Stock | 14,293 | 11.18 | 159.8K | 209,810 | — | ↗ |
| 2021-03-26 | Malik Vikram | Director | A-Award | A | Common Stock | 18,011 | 0.00 | — | 53,724 | — | ↗ |
| 2021-03-26 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Common Stock | 48,853 | 0.00 | — | 489,280 | — | ↗ |
| 2021-02-25 | Muilenburg Crystal | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 11.50 | 230.0K | 20,000 | — | ↗ |
| 2021-02-18 | Medytox Inc. | 10% Owner | — | D | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 6,762,652 | — | ↗ |
| 2021-02-05 | Parschauer Karah Herdman | Director | A-Award | A | Common Stock | 19,313 | 0.00 | — | 19,313 | — | ↗ |
| 2021-02-05 | Malik Vikram | Director | A-Award | A | Common Stock | 19,313 | 0.00 | — | 35,713 | — | ↗ |
| 2021-02-05 | HAYMAN ROBERT | Director | A-Award | A | Common Stock | 19,313 | 0.00 | — | 19,313 | — | ↗ |
| 2021-02-05 | GILL DAVID N | Director | A-Award | A | Common Stock | 19,313 | 0.00 | — | 24,313 | — | ↗ |
| 2021-02-05 | FARRELL PETER C | Director | A-Award | A | Common Stock | 19,313 | 0.00 | — | 19,313 | — | ↗ |
| 2021-02-05 | BLANK SIMONE | Director | A-Award | A | Common Stock | 19,313 | 0.00 | — | 19,313 | — | ↗ |
| 2021-01-27 | SILVERNAIL LAUREN P | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 180,689 | — | ↗ |
| 2021-01-27 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Common Stock | 266,667 | 0.00 | — | 440,427 | — | ↗ |
| 2021-01-27 | Jafar Michael M. | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 219,851 | — | ↗ |
| 2021-01-27 | Avelar Rui | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 224,103 | — | ↗ |
| 2021-01-25 | SILVERNAIL LAUREN P | Officer | S-Sale | D | Common Stock | 2,699 | 7.46 | 20.1K | 90,689 | — | ↗ |
| 2021-01-25 | MOATAZEDI DAVID | Director / Officer | S-Sale | D | Common Stock | 8,310 | 7.46 | 62.0K | 173,760 | — | ↗ |
| 2021-01-25 | Jafar Michael M. | Officer | S-Sale | D | Common Stock | 2,699 | 7.46 | 20.1K | 174,851 | — | ↗ |
| 2021-01-25 | Avelar Rui | Officer | S-Sale | D | Common Stock | 2,699 | 7.46 | 20.1K | 134,103 | — | ↗ |
| 2020-10-28 | Jafar Michael M. | Officer | A-Award | A | Common Stock | 48,550 | 0.00 | — | 177,550 | — | ↗ |
| 2020-05-13 | SILVERNAIL LAUREN P | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 93,388 | — | ↗ |
| 2020-05-13 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 182,070 | — | ↗ |
| 2020-05-13 | Jafar Michael M. | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 129,000 | — | ↗ |
| 2020-05-13 | Avelar Rui | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 136,802 | — | ↗ |
| 2020-01-23 | SILVERNAIL LAUREN P | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 53,388 | — | ↗ |
| 2020-01-23 | Romine Kristine | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
| 2020-01-23 | Parschauer Karah Herdman | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
| 2020-01-23 | Malik Vikram | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
| 2020-01-23 | MOATAZEDI DAVID | Director / Officer | A-Award | A | Common Stock | 82,070 | 0.00 | — | 82,070 | — | ↗ |
| 2020-01-23 | Jafar Michael M. | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 10.19 | 458.6K | 45,000 | — | ↗ |
| 2020-01-23 | Hau Bosun | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
| 2020-01-23 | HAYMAN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
| 2020-01-23 | GILL DAVID N | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
| 2020-01-23 | FARRELL PETER C | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
| 2020-01-23 | BLANK SIMONE | Director | A-Award | A | Stock Option (Right to Buy) | 23,458 | 10.19 | 239.0K | 23,458 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-101.1K
Shares Outstanding
65.06M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David Moatazedi President and Chief Executive Officer | 775.0K | — | 3.89M | 1.30M | 429.0K | 24.9K | 6.41M | 80.83% | ↗ |
| 2 | 2025 | Tatjana Mitchell Chief Financial Officer | 154.2K | 100.0K | 1.42M | 1.37M | 111.2K | 9.3K | 3.16M | 88.15% | ↗ |
| 3 | 2025 | Sandra Beaver Former Chief Financial Officer | 231.9K | — | 968.6K | 484.7K | — | 14.6K | 1.70M | 85.50% | ↗ |
| 4 | 2025 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 545.4K | — | 645.8K | 323.2K | 166.6K | 18.2K | 1.70M | 57.03% | ↗ |
| 5 | 2025 | Tomoko Yamagishi-Dressler Former Chief Marketing Officer | 285.2K | — | 484.3K | 242.4K | 73.4K | 502.8K | 1.59M | 45.76% | ↗ |
| 6 | 2024 | David Moatazedi President and Chief Executive Officer | 743.8K | — | 3.55M | 1.78M | 900.0K | 28.2K | 7.00M | 76.11% | ↗ |
| 7 | 2024 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 515.7K | — | 1.61M | 463.6K | 280.5K | 14.9K | 2.88M | 71.88% | ↗ |
| 8 | 2024 | Sandra Beaver Chief Financial Officer | 477.6K | — | 694.5K | 463.6K | 260.8K | 14.8K | 1.91M | 60.59% | ↗ |
| 9 | 2024 | Sandra Beaver Former Chief Financial Officer | 477.6K | — | 694.5K | 463.6K | 260.8K | 14.8K | 1.91M | 60.59% | ↗ |
| 10 | 2024 | Tomoko Yamagishi-Dressler Former Chief Marketing Officer | 429.5K | — | 486.2K | 324.5K | 233.1K | 14.7K | 1.49M | 54.48% | ↗ |
| 11 | 2024 | Tomoko Yamagishi-Dressler Chief Marketing Officer | 429.5K | — | 486.2K | 324.5K | 233.1K | 14.7K | 1.49M | 54.48% | ↗ |
| 12 | 2023 | David Moatazedi President and Chief Executive Officer | 687.5K | — | 7.42M | 2.08M | 1.02M | 41.9K | 11.24M | 84.46% | ↗ |
| 13 | 2023 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 487.8K | — | 1.41M | 692.0K | 320.6K | 14.8K | 2.93M | 71.90% | ↗ |
| 14 | 2023 | Sandra Beaver Former Chief Financial Officer | 437.5K | — | 1.03M | 692.0K | 287.9K | 14.8K | 2.46M | 69.91% | ↗ |
| 15 | 2023 | Sandra Beaver Chief Financial Officer | 437.5K | — | 1.03M | 692.0K | 287.9K | 14.8K | 2.46M | 69.91% | ↗ |
| 16 | 2023 | Tomoko Yamagishi-Dressler Chief Marketing Officer | 151.3K | 35.0K | 595.6K | 595.6K | 271.5K | 43.2K | 1.69M | 70.39% | ↗ |
| 17 | 2023 | Tomoko Yamagishi-Dressler Former Chief Marketing Officer | 151.3K | 35.0K | 595.6K | 595.6K | 271.5K | 43.2K | 1.69M | 70.39% | ↗ |
| 18 | 2022 | David Moatazedi President and Chief Executive Officer | 596.9K | — | 1.17M | 1.16M | 643.2K | 28.0K | 3.60M | 64.77% | ↗ |
| 19 | 2022 | Sandra Beaver Chief Financial Officer | 136.8K | 100.0K | 330.2K | 1.13M | 135.1K | 313.00 | 1.83M | 79.63% | ↗ |
| 20 | 2022 | Lauren Silvernail Former Chief Financial Officer and Executive Vice President, Corporate Development | 184.2K | — | 582.3K | 290.4K | — | 375.7K | 1.43M | 60.92% | ↗ |
| 21 | 2022 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 469.0K | — | 292.5K | 290.4K | 202.4K | 10.6K | 1.26M | 46.08% | ↗ |
| 22 | 2021 | David Moatazedi President and Chief Executive Officer | 571.9K | — | 2.30M | — | 632.5K | 25.2K | 3.53M | 65.17% | ↗ |
| 23 | 2021 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 445.0K | — | 582.3K | — | 207.4K | 7.7K | 1.24M | 46.87% | ↗ |
| 24 | 2021 | Lauren Silvernail Chief Financial Officer and Executive Vice President, Corporate Development | 439.9K | — | 582.3K | — | 176.8K | 13.2K | 1.21M | 48.04% | ↗ |
| 25 | 2021 | Lauren Silvernail Former Chief Financial Officer and Executive Vice President, Corporate Development | 439.9K | — | 582.3K | — | 176.8K | 13.2K | 1.21M | 48.04% | ↗ |
| 26 | 2020 | David Moatazedi President and Chief Executive Officer | 527.1K | — | 1.23M | 815.9K | 720.5K | 7.7K | 3.30M | 62.00% | ↗ |
| 27 | 2020 | Michael Jafar Former Chief Commercial Officer | 342.3K | — | 573.4K | 412.0K | 226.5K | 2.6K | 1.56M | 63.30% | ↗ |
| 28 | 2020 | Lauren Silvernail Chief Financial Officer and Executive Vice President, Corporate Development | 407.3K | — | 423.3K | 258.7K | 222.7K | 3.8K | 1.32M | 51.83% | ↗ |
| 29 | 2020 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 403.3K | — | 423.3K | 258.7K | 222.6K | 5.9K | 1.31M | 51.91% | ↗ |
| 30 | 2019 | David Moatazedi President and Chief Executive Officer | 550.0K | — | — | 1.17M | 555.5K | 3.5K | 2.28M | 51.33% | ↗ |
| 31 | 2019 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 400.0K | — | — | 561.5K | 861.6K | 13.5K | 1.84M | 30.57% | ↗ |
| 32 | 2019 | Lauren Silvernail Chief Financial Officer and Executive Vice President, Corporate Development | 425.0K | — | — | 421.1K | 171.7K | 3.5K | 1.02M | 41.23% | ↗ |
| 33 | 2019 | Michael Jafar Former Chief Commercial Officer | 345.0K | — | — | 421.1K | 139.4K | — | 905.5K | 46.51% | ↗ |
| 34 | 2018 | Murthy Simhambhatla Former President and Chief Executive Officer | 251.9K | — | 1.20M | 4.92M | — | 464.3K | 6.84M | 89.52% | ↗ |
| 35 | 2018 | David Moatazedi President and Chief Executive Officer | 361.7K | 75.0K | — | 5.00M | 361.6K | — | 5.79M | 86.22% | ↗ |
| 36 | 2018 | Michael Jafar Chief Marketing Officer | 187.1K | 324.5K | 1.42M | 1.98M | — | 25.0K | 3.93M | 86.34% | ↗ |
| 37 | 2018 | Lauren Silvernail Chief Financial Officer and Executive Vice President, Corporate Development | 253.4K | — | 673.2K | 2.60M | 101.1K | 25.0K | 3.66M | 89.62% | ↗ |
| 38 | 2018 | Rui Avelar, M.D. Chief Medical Officer and Head of Research and Development | 367.9K | — | 1.20M | 1.43M | 160.0K | — | 3.16M | 83.28% | ↗ |
| 39 | 2017 | Murthy Simhambhatla Former President and Chief Executive Officer | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Moatazedi | President, Chief Executive Officer & Director | 1M | male |
| Rui Avelar C.CFP Dip.SportMed | Chief Medical Officer and Head of Research & Development | 811.1K | — |
| Tatjana Mitchell | Chief Financial Officer | 753.2K | female |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer | 677.4K | female |
| Nareg Sagherian | Head of Global Investor Relations & Corporate Communications | — | male |
| Kurt Knab | Senior Vice President of Sales | — | male |
| Jessica Novak | Senior Vice President of Human Resources | — | female |
| Jeffrey J. Plumer | Corporate Secretary | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EOLS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
